Published in Am J Med on May 01, 2003
Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum (2006) 2.64
Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol (2004) 1.75
Effects of cardiotonic steroids on dermal collagen synthesis and wound healing. J Appl Physiol (1985) (2008) 1.45
Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol (2011) 1.21
Hospital-acquired acute kidney injury in the elderly. Nat Rev Nephrol (2010) 1.10
Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol (2008) 1.05
Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. J Urol (2008) 1.04
Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum (2009) 0.99
Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol (2010) 0.92
Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. Pediatr Radiol (2007) 0.87
Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol (2009) 0.86
Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol (2008) 0.86
Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol (2010) 0.86
Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol (2006) 0.85
Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol (2012) 0.85
Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol (2010) 0.84
Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol (2013) 0.83
Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal (2015) 0.83
Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res (2011) 0.82
Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging (2009) 0.81
Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res (2011) 0.80
Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. J Cell Commun Signal (2012) 0.78
Understanding nephrogenic systemic fibrosis. Int J Nephrol (2012) 0.76
Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol (2011) 0.75
Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging. Insights Imaging (2012) 0.75
Nephrogenic systemic fibrosis: time for the requiem? Indian J Dermatol (2011) 0.75
The myofibroblast: one function, multiple origins. Am J Pathol (2007) 8.64
Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest (2004) 5.97
Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol (2012) 4.13
Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med (2005) 2.86
Dual roles of IL-4 in lung injury and fibrosis. J Immunol (2003) 2.75
Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol (2003) 2.69
Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2009) 2.68
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Patient perspectives on the impact of fibromyalgia. Patient Educ Couns (2008) 2.57
Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med (2005) 2.52
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum (2004) 2.48
Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum (2008) 2.22
Regulation of telomerase activity in rat lung fibroblasts. Am J Respir Cell Mol Biol (2002) 2.07
FIZZ1 stimulation of myofibroblast differentiation. Am J Pathol (2004) 2.06
Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum (2005) 1.98
Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol (2003) 1.94
Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med (2002) 1.87
Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol (2009) 1.87
Telomerase regulation of myofibroblast differentiation. Am J Respir Cell Mol Biol (2006) 1.84
Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol (2004) 1.83
PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2007) 1.74
Self-regulatory deficits in fibromyalgia and temporomandibular disorders. Pain (2010) 1.68
The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc Am Thorac Soc (2006) 1.65
Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J Cell Physiol (2007) 1.61
Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum (2002) 1.58
Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study. Brain Behav Immun (2012) 1.53
Fibromyalgia syndrome. J Rheumatol (2005) 1.49
CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine (2003) 1.42
Gut-enriched Krüppel-like factor interaction with Smad3 inhibits myofibroblast differentiation. Am J Respir Cell Mol Biol (2006) 1.38
Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest (2007) 1.36
New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm Res (2007) 1.35
Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer (2003) 1.35
Notch1 signaling in FIZZ1 induction of myofibroblast differentiation. Am J Pathol (2009) 1.34
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
Gender-based differences in bleomycin-induced pulmonary fibrosis. Am J Pathol (2005) 1.25
Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol (2011) 1.22
Eosinophils and T lymphocytes possess distinct roles in bleomycin-induced lung injury and fibrosis. J Immunol (2003) 1.21
Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol (2005) 1.18
Epigenetic regulation of myofibroblast differentiation by DNA methylation. Am J Pathol (2010) 1.16
CCAAT/enhancer-binding protein beta isoforms and the regulation of alpha-smooth muscle actin gene expression by IL-1 beta. J Immunol (2004) 1.16
Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids (2007) 1.14
A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol (2009) 1.13
Chronic inhaled ovalbumin exposure induces antigen-dependent but not antigen-specific inhalational tolerance in a murine model of allergic airway disease. Am J Pathol (2004) 1.12
Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther (2008) 1.11
Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis. Inflamm Regen (2011) 1.11
A profibrotic function of IL-12p40 in experimental pulmonary fibrosis. J Immunol (2002) 1.11
Sleep stage dynamics in fibromyalgia patients and controls. Sleep Med (2008) 1.10
The liver is a common non-exocrine target in primary Sjögren's syndrome: a retrospective review. BMC Gastroenterol (2002) 1.10
Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther (2013) 1.03
Role of stem cell factor and bone marrow-derived fibroblasts in airway remodeling. Am J Pathol (2009) 1.02
Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. Proc Am Thorac Soc (2008) 1.02
FIZZ2/RELM-β induction and role in pulmonary fibrosis. J Immunol (2011) 1.01
The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med (2007) 1.00
Animal models of pulmonary fibrosis. Methods Mol Med (2005) 0.99
Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol (2009) 0.99
Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol (2008) 0.99
Myofibroblasts. Curr Opin Rheumatol (2013) 0.98
Rheumatoid arthritis and salivary biomarkers of periodontal disease. J Clin Periodontol (2010) 0.98
Expression of polycomb group protein EZH2 in nevi and melanoma. J Cutan Pathol (2007) 0.97
Self-directed learning of basic musculoskeletal ultrasound among rheumatologists in the United States. Arthritis Care Res (Hoboken) (2010) 0.96
Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol (2013) 0.96
Involvement of serum response factor isoforms in myofibroblast differentiation during bleomycin-induced lung injury. Am J Respir Cell Mol Biol (2003) 0.95
BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol (2006) 0.95
Objective measures of disordered sleep in fibromyalgia. J Rheumatol (2009) 0.94
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
Impaired sleep quality in fibromyalgia: Detection and quantification with ECG-based cardiopulmonary coupling spectrograms. Sleep Med (2009) 0.92
Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol (2013) 0.92
Diclofenac delays micropore closure following microneedle treatment in human subjects. J Control Release (2012) 0.92
Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J Immunol (2008) 0.92
Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. Arthritis Res Ther (2005) 0.91
Characterization of the effect of interleukin-10 on silica-induced lung fibrosis in mice. Am J Respir Cell Mol Biol (2004) 0.91
Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol (2011) 0.91
Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-alpha on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol (2009) 0.91
Memory beliefs and function in fibromyalgia patients. J Psychosom Res (2005) 0.90
Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem (2006) 0.90
Erythromycin-induced CXCR4 expression on microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol (2009) 0.90
Association of smoking and chronic pain syndromes in Kentucky women. J Pain (2011) 0.90
Mesenchymal-specific deletion of C/EBPβ suppresses pulmonary fibrosis. Am J Pathol (2012) 0.89
The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med (2009) 0.88
TGF-beta1-induced Smad 3 binding to the Smad 7 gene: knockout of Smad 7 gene transcription by sense phosphorothioate oligos, autoregulation, and effect on TGF-beta1 secretion: bleomycin acts through TGF-beta1. J Cell Biochem (2003) 0.88
Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem (2004) 0.87
Lung bone marrow-derived hematopoietic progenitor cells enhance pulmonary fibrosis. Am J Respir Crit Care Med (2013) 0.87
Association of fibromyalgia with altered skeletal muscle characteristics which may contribute to postexertional fatigue in postmenopausal women. Arthritis Rheum (2013) 0.87
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat Rev Rheumatol (2012) 0.87
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther (2011) 0.87
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1. Am J Pathol (2013) 0.86
Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther (2012) 0.86
Degos' disease mimicking vasculitis. Arthritis Rheum (2004) 0.86
Toll-like receptor 9 activation is a key mechanism for the maintenance of chronic lung inflammation. Am J Respir Crit Care Med (2009) 0.86
The role of urokinase in idiopathic pulmonary fibrosis and implication for therapy. Expert Opin Investig Drugs (2008) 0.86
Prostaglandin E2 activates Rap1 via EP2/EP4 receptors and cAMP-signaling in rheumatoid synovial fibroblasts: involvement of Epac1 and PKA. Prostaglandins Other Lipid Mediat (2009) 0.86
The association of adverse pregnancy events and cardiovascular disease in women 50 years of age and older. J Womens Health (Larchmt) (2011) 0.86
Prostaglandin E2 induction during mouse adenovirus type 1 respiratory infection regulates inflammatory mediator generation but does not affect viral pathogenesis. PLoS One (2013) 0.85
Prevalence of antigliadin antibodies in patients with psoriasis is not elevated compared with controls. Am J Clin Dermatol (2007) 0.85
Intrauterine group A streptococcal infections are exacerbated by prostaglandin E2. J Immunol (2013) 0.85
New insights into the benefits of exercise for muscle health in patients with idiopathic inflammatory myositis. Curr Rheumatol Rep (2014) 0.84